Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $35 to $32.
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $35 to $32.